pharmaphorum

NOVEMBER 3, 2021

A real-world study of digital therapeutic (DTx) for opioid use disorder has found that patient show used it had 46% fewer hospital stays than a control group, saving more than $2,700 over a nine-month period. The study of Pear Therapeutics’ reSET-O found that the total cost of hospital and clinician costs were $11,141 among 64 patients who were prescribed the DTx but didn’t use it, but fell to $8,733 among active users of the 12-week course.

Hospitals 132

Hospitals 132

Pharma Times

NOVEMBER 5, 2021

The trial evaluated the investigational medicine in non-hospitalised adult patients with COVID-19 who are at high-risk of progressing to severe illness

127

127

Pharma Marketing Network

NOVEMBER 3, 2021

In the last 2 years, and accelerated by Covid, native advertising has exploded across healthcare for DTC and HCP marketing. Native ads have been adopted by all healthcare industries including pharma, device, health systems, retailers, pharmacies, payers, and the gamut of regional service providers. But there are still a handful of advertiser holdouts, and they are missing out on highly engaged audiences.

105

105

NY Times

OCTOBER 30, 2021

It was the state’s first lethal injection since 2015, when it halted executions after using the wrong drug in one instance and allowing a prisoner to regain consciousness in another.

98

98

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Communication

pharmaphorum

NOVEMBER 1, 2021

Daiichi Sankyo has launched its oncolytic virus therapy Delytact in Japan – its first world market – as a treatment for malignant glioma, an aggressive form of brain cancer. Delytact (teserpaturev) is a genetically engineered oncolytic herpes simplex virus type 1 (HSV-1) that was approved for marketing in Japan earlier this year, and received pricing approval in August at 1.43 million yen (around $12,500) per dose, according to a Pharma Japan report.

Chemotherapy 122

Chemotherapy Hospitals 122

Pharma Times

NOVEMBER 2, 2021

93% of clinicians felt that remote medicine was worse than in-person consultations in terms of accuracy

124

124

Outsourcing Pharma

NOVEMBER 1, 2021

The cloud software firmâs Digital Clinical Trials Survey Report reveals that the industry is adapting to challenges caused by COVID-19 and other factors.

103

103

pharmaphorum

NOVEMBER 5, 2021

An oral antiviral drug developed by Pfizer has been shown to dramatically cut the risk of hospitalisation or death from COVID-19 when given in the early stages of infection. The phase 3 trial found that Paxlovid – which combines new protease inhibitor PF-07321332 with already-approved HIV drug ritonavir – reduced the risk of hospitalisation or death by 89% when given to newly-diagnosed adults who were at risk of developing severe COVID-19 in the EPIC-HR trial.

Hospitals 115

Hospitals Drug Development 115

Pharma Times

NOVEMBER 1, 2021

HRT treats menopause symptoms by replacing hormones that are at a lower level for those experiencing it

122

122

NY Times

NOVEMBER 5, 2021

Pfizer’s is the second pill to show effectiveness against Covid-19, and it is the first purpose-built to attack the virus that causes the disease.

98

98

Advertisement

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

Drug Patent Watch

NOVEMBER 3, 2021

This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Lithuania. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in Lithuania? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceutical Companies 88

Pharmaceutical Companies Pharmaceutical Companies 88

pharmaphorum

NOVEMBER 1, 2021

Novartis has claimed FDA approval for one of its ‘wild card’ drugs – Scemblix – a first-in-class STAMP inhibitor for patients with previously-treated chronic myeloid leukaemia (CML). Scemblix (asciminib) was one of a clutch of high risk, high reward drug candidates for a range of diseases that Novartis chief executive Vas Narasimhan said last year were flying under-the-radar of industry watchers, but could potentially develop into blockbusters.

Labelling 114

Labelling 114

Pharma Times

NOVEMBER 1, 2021

Anyone who received their second dose at least six months ago can now receive their booster at one of these sites

113

113

Outsourcing Pharma

NOVEMBER 1, 2021

A former employee of Tellus Clinical Research in Miami has admitted to charges related to a conspiracy to falsify data on a list of clinical drug trials.

95

95

Speaker: Joe Sharpe and James Carlson

Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.

NY Times

NOVEMBER 4, 2021

Start-up investors have often suspended skepticism while chasing a hot deal. The trial of Ms. Holmes, the founder of Theranos, has put that behavior under the spotlight.

80

80

pharmaphorum

NOVEMBER 5, 2021

Novartis has chalked up another successful trial for its targeted factor B inhibitor iptacopan, an orally-active drug trying to challenge antibody-based therapies for diseases associated with the complement pathway. A phase 2 trial of iptacopan in patients with the rare kidney disease C3 glomerulopathy (C3G) – which causes progressive kidney failure and has no approved treatments – showed reductions in kidney damage with the drug that Novartis said were “clinically important.” C3G of

105

105

Pharma Times

NOVEMBER 4, 2021

Partnership will establish an in-house liquid biopsy testing service, using Guardant Health’s proprietary digital sequencing platform

98

98

Outsourcing Pharma

NOVEMBER 1, 2021

The trial will evaluate a weekly regimen of islatravir and lnecapavir in HIV patients who are virologically suppressed while on antiretroviral therapies.

88

88

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

NY Times

NOVEMBER 2, 2021

In one of the first cases to be brought against drug manufacturers over the crisis, a judge ruled that there was “simply no evidence” the companies were liable in the epidemic.

77

77

pharmaphorum

NOVEMBER 4, 2021

After more than 20 years, Novartis has finally decided to sell its substantial share in fellow Swiss pharma group Roche for $20.7 billion, a decent return on its original $5 billion investment. The agreement will see Novartis lose its one-third voting share stake in Roche, after agreeing to sell 53.3 million Roche bearer shares at their average price over 20 days prior to 2 November, when the deal was agreed.

105

105

Pharma Times

NOVEMBER 3, 2021

Back in 2019, esketamine was commercialised as Spravato, described as a “breakthrough” medication used to treat depression

99

99

Drug Patent Watch

OCTOBER 30, 2021

This chart shows the pharmaceutical companies with the most patents in Norway. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Norway? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceutical Companies 76

Pharmaceutical Companies Pharmaceutical Companies 76

Advertisement

Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.

NY Times

NOVEMBER 4, 2021

The authorization of Merck’s easy-to-use Covid treatment, molnupiravir, is a step toward taming the pandemic.

95

95

pharmaphorum

NOVEMBER 4, 2021

Routine vaccination with human papillomavirus vaccines have resulted in an 87% reduction in cervical cancer cases in England, and could even see the need for smear tests phased out in future, according to a new study. The jabs with have been offered by the NHS to girls between the ages of 12 and 13 since 2008, with more than 10 million doses administered since then, and from September 2019 was also offered to boys in the same age group.

Vaccines 105

Vaccines 105

Pharma Times

NOVEMBER 4, 2021

The research paper, published in the Lancet and funded by Cancer Research UK, considered all cervical cancers diagnosed in England among women aged 20-64 between January 2006 and June 2019

Vaccines 84

Vaccines 84

Outsourcing Pharma

NOVEMBER 2, 2021

The global pharmaceutical industry event is returning to the real world November 9-11 this year, with online content for professionals opting not to travel.

72

72

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

Drug Channels

NOVEMBER 5, 2021

Today’s guest post comes from Ashleigh Burdette, Senior Director of Clinical Innovation at Biologics by McKesson. Ashleigh explains how biopharma companies can help patients become more adherent and achieve better health outcomes by partnering with an experienced specialty pharmacy that offers risk-based care. . To learn more about the risk-based care approach, download the free whitepaper: Risk-Based Care Helps Cancer Treatment Adherence.

Specialty Pharmacies 70

Specialty Pharmacies 70

pharmaphorum

NOVEMBER 2, 2021

Rocketing sales of COVID-19 vaccine Comirnaty have allowed Pfizer to raise its full-year forecasts for the shot once again to a whopping $36 billion, more than double its predictions just a few months ago. Fuelled by extensions to vaccination programmes to include children and booster shots, the BioNTech-partnered jab made nearly $13 billion in the third quarter, around $2 billion more than analyst consensus forecasts.

Vaccines 98

Vaccines 98

Pharma Times

NOVEMBER 3, 2021

Dunad will apply its own platform to generate the novel covalent and targeted protein degrading small molecule drugs

101

101

NY Times

OCTOBER 30, 2021

Most Medicare beneficiaries don’t compare plans during open enrollment season, and may be paying more, or accepting more restrictions, than they should.

69

69

Drug Patent Watch

NOVEMBER 4, 2021

Annual Drug Patent Expirations for MYCAPSSA Mycapssa is a drug marketed by Chiasma and is included in one NDA. It is available from one supplier. There are seven patents protecting…. The post New patent for Chiasma drug MYCAPSSA appeared first on DrugPatentWatch - Make Better Decisions.

59

59